N-Formyl leurosine derivatives in a dosage form effective for treating lymphoid leukemia
US4279816A · kind A · utility
0Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 5, 1975 |
| Grant date | Jul 21, 1981 |
| Priority date | — |
| Expiry date | Feb 5, 1995 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
New leurosine derivatives of the general formula (1), ##STR1## wherein R stands for hydrogen or formyl, or pharmaceutically acceptable acid addition salts thereof were prepared by oxidizing leurosine or an acid addition salt thereof, optionally formylating the thus-obtained product and then separating, and, if desired, converting any of the free bases into its acid addition salt.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.